RU2017134875A3 - - Google Patents

Download PDF

Info

Publication number
RU2017134875A3
RU2017134875A3 RU2017134875A RU2017134875A RU2017134875A3 RU 2017134875 A3 RU2017134875 A3 RU 2017134875A3 RU 2017134875 A RU2017134875 A RU 2017134875A RU 2017134875 A RU2017134875 A RU 2017134875A RU 2017134875 A3 RU2017134875 A3 RU 2017134875A3
Authority
RU
Russia
Application number
RU2017134875A
Other versions
RU2764992C2 (ru
RU2017134875A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017134875A publication Critical patent/RU2017134875A/ru
Publication of RU2017134875A3 publication Critical patent/RU2017134875A3/ru
Application granted granted Critical
Publication of RU2764992C2 publication Critical patent/RU2764992C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21004Trypsin (3.4.21.4)
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2017134875A 2015-03-31 2016-03-31 Новые способы селекции эпитопов RU2764992C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562140955P 2015-03-31 2015-03-31
US62/140,955 2015-03-31
US201562283118P 2015-08-21 2015-08-21
US62/283,118 2015-08-21
PCT/EP2016/057164 WO2016156545A1 (en) 2015-03-31 2016-03-31 New methods for epitope selection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2022100590A Division RU2022100590A (ru) 2015-03-31 2016-03-31 Новые способы селекции эпитопов

Publications (3)

Publication Number Publication Date
RU2017134875A RU2017134875A (ru) 2019-05-06
RU2017134875A3 true RU2017134875A3 (ru) 2019-09-13
RU2764992C2 RU2764992C2 (ru) 2022-01-24

Family

ID=55701934

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2022100590A RU2022100590A (ru) 2015-03-31 2016-03-31 Новые способы селекции эпитопов
RU2017134875A RU2764992C2 (ru) 2015-03-31 2016-03-31 Новые способы селекции эпитопов

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2022100590A RU2022100590A (ru) 2015-03-31 2016-03-31 Новые способы селекции эпитопов

Country Status (17)

Country Link
US (2) US11161901B2 (ru)
EP (1) EP3277724A1 (ru)
JP (1) JP6967507B2 (ru)
KR (1) KR20170136551A (ru)
CN (1) CN107531792A (ru)
AU (2) AU2016240208B2 (ru)
BR (1) BR112017021026A2 (ru)
CA (1) CA2981108A1 (ru)
HK (1) HK1249124A1 (ru)
IL (1) IL254795B2 (ru)
MA (1) MA41842A (ru)
MX (1) MX2017012284A (ru)
NZ (1) NZ735823A (ru)
RU (2) RU2022100590A (ru)
SG (1) SG11201707945TA (ru)
WO (1) WO2016156545A1 (ru)
ZA (1) ZA201707369B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10753928B2 (en) 2015-12-14 2020-08-25 Morinaga Institute Of Biological Science, Inc. Protein detection method, and protein immunoassay method
US11136362B2 (en) * 2016-03-10 2021-10-05 The Board Of Trustees Of The Leland Stanford Junior University Peptide modulators of specific calcineurin protein-protein interactions
GB201614884D0 (en) * 2016-09-01 2016-10-19 Oblique Therapeutics Ab Method
GB201617002D0 (en) * 2016-10-06 2016-11-23 Oblique Therapeutics Ab Multi-protease method
CN107991495B (zh) * 2017-11-27 2020-08-07 河南科技大学 一种提高膜蛋白序列检测覆盖率的质谱样品的制备方法
JP6712369B2 (ja) * 2018-05-29 2020-06-24 株式会社森永生科学研究所 抗ペプチド抗体の製造方法及び設計方法
GB202019522D0 (en) * 2020-12-10 2021-01-27 Oblique Therapeutics Ab Epitopes and antibodies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2094276C (en) * 1990-10-18 2005-08-23 Keld Dano Antibodies against the urokinase receptor and their use
CN101274959A (zh) * 1995-03-17 2008-10-01 益得生物医学公司 抗蛋白酶k降解的脑膜炎奈瑟氏球菌表面蛋白
IL117483A (en) * 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
IL138946A0 (en) 2000-10-11 2001-11-25 Compugen Ltd Method for the identification of peptides and proteins
CA2453406A1 (en) 2001-07-13 2003-01-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Methods for reducing immunogenicity of polypeptides
CA2501000C (en) 2002-10-03 2015-05-26 Norman Leigh Anderson High sensitivity quantitation of peptides by mass spectrometry
US7632686B2 (en) 2002-10-03 2009-12-15 Anderson Forschung Group High sensitivity quantitation of peptides by mass spectrometry
MEP31508A (en) 2003-07-15 2010-10-10 Amgen Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
US20070281986A1 (en) * 2004-02-03 2007-12-06 Collier Gregory R Methods and Compositions for Modulating Satiety
WO2006005472A1 (en) * 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with vanilloid receptor 1 (vr1)
US20060292639A1 (en) * 2004-08-13 2006-12-28 Adolor Corporation Splice variant of the vanilloid receptor VR1A
WO2006047417A2 (en) * 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection of cannabinoid receptor biomarkers and uses thereof
SE0403139D0 (sv) 2004-12-23 2004-12-23 Nanoxis Ab Device and use thereof
JP2008175814A (ja) * 2006-12-21 2008-07-31 Eisai R & D Management Co Ltd 尿中タンパク質分子の検出・定量による糖尿病性腎症の検査方法及びそれに使用するキット
WO2008120684A1 (ja) 2007-03-30 2008-10-09 Yamaguchi University 急性中枢神経障害の予後判定方法
ES2579554T3 (es) 2008-05-09 2016-08-12 Abbvie Deutschland Gmbh & Co Kg Anticuerpos para el receptor de productos terminales de glicación avanzada (RAGE) y usos de los mismos
US20120128646A1 (en) 2009-02-17 2012-05-24 Kathryn Haskins Methods and compositions for the treatment of autoimmune disease
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
US9383367B1 (en) 2010-12-07 2016-07-05 Chunli Liu Methods of detecting conjugation site-specific and hidden epitope/antigen
US9476888B2 (en) 2011-08-08 2016-10-25 Syddansk Universitet Method and antibodies for the identification of ubiquitinated proteins and sites of ubiquitination
SG11201506244VA (en) 2013-03-13 2015-09-29 Prothena Biosciences Ltd Tau immunotherapy
GB201617002D0 (en) 2016-10-06 2016-11-23 Oblique Therapeutics Ab Multi-protease method

Also Published As

Publication number Publication date
IL254795B1 (en) 2023-05-01
HK1249124A1 (zh) 2018-10-26
EP3277724A1 (en) 2018-02-07
RU2022100590A (ru) 2022-03-10
JP6967507B2 (ja) 2021-11-17
JP2018509942A (ja) 2018-04-12
SG11201707945TA (en) 2017-10-30
NZ735823A (en) 2023-07-28
US20180111990A1 (en) 2018-04-26
IL254795A0 (en) 2017-12-31
CA2981108A1 (en) 2016-10-06
KR20170136551A (ko) 2017-12-11
IL254795B2 (en) 2023-09-01
RU2764992C2 (ru) 2022-01-24
BR112017021026A2 (pt) 2018-11-06
US11161901B2 (en) 2021-11-02
US20220073607A1 (en) 2022-03-10
AU2022202251A1 (en) 2022-04-21
AU2016240208A1 (en) 2017-10-19
US11912765B2 (en) 2024-02-27
CN107531792A (zh) 2018-01-02
ZA201707369B (en) 2019-02-27
AU2016240208B2 (en) 2022-01-27
WO2016156545A1 (en) 2016-10-06
MA41842A (fr) 2018-02-06
RU2017134875A (ru) 2019-05-06
MX2017012284A (es) 2018-06-20

Similar Documents

Publication Publication Date Title
BR112018002571A2 (ru)
BR112018002847A2 (ru)
RU2017134875A3 (ru)
BE2015C044I2 (ru)
BR0009349B1 (ru)
BR0003401B1 (ru)
CN303075599S (ru)
CN303075377S (ru)
CN303069892S (ru)
CN303069071S (ru)
CN303080675S (ru)
BRMU8401619Y1 (ru)
CN303083530S (ru)
CN303089344S (ru)
BR0112121B1 (ru)
BR0110273B1 (ru)
BR0010150B1 (ru)
BR0009994B1 (ru)
BR0009942B1 (ru)
BR0009761B1 (ru)
BR0008874B1 (ru)
BR0009717B1 (ru)
BR0009649B1 (ru)
BR0009373B1 (ru)
CN303090505S (ru)